Vel Sciences

VEL Sciences is an pre-IND, biotechnology company developing immune-based prophylactic and therapeutic treatments for cancer and against antigenically variable pathogens (AVPs) and diseases (HCV, HIV, TB, Coronavirus, malaria, influenza, dengue/zika, etc.). The revolutionary approach is based on a new class of vaccine immunogens, called Variable Epitope Libraries TM©, or (VELs TM©). In layman terms, VELs create coding of the millions of permutations and variations of responses to changes in viruses. VELs are then embedded into the immunology treatment and introduced into the body. VELs trigger B cell and T cell memory responses and then the immunological escape is avoided as the new variant faces the corresponding epitope in the immunological process. Our company’s proprietary platform - the Variable Epitope Library (VEL)- has proven to elicit strong and sustained tumor specific T-cell responses in animal models leading to best-in-class therapeutic efficacy. VEL Sciences immunotherapies are designed to be an off-the-shelf, solution. The VELs are characterized by amino acid substitutions (mutations) in specific regions (epitopes) of antigens derived from cancer cells or AVPs. The immunotherapeutic solutions are super-complex combinatorial mixtures of immunogens that represent/reflect actual and potential antigenic composition (mutational landscape) of antigenically variable targets (AVTs) as they mutate. Immune systems primed with VELs produce unprecedented large repertoires of T and B cells capable of inhibiting tumor growth and metastases, as well as eliminating the cells infected with AVPs and/or neutralizing the pathogens by vaccine-induced antibodies, respectively. “ We can supply solutions from our pipeline or from custom VELs. If you have any questions or wish to revolutionize the production of your medicines through the use of our platform, please email us and we will be more than happy to help. inquiry@velsciences.com.